Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Gene Therapy for Parkinson's Disease
jRCT2033260155Active, not recruiting
- Start
- May 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT0003X in Parkinson's disease (PD). Primary endpoint: Primary: Long-term tolerability, safety, and efficacy. Started May 2026; status: active, not recruiting.
02
Drugs
GT0003X
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2033260155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260155.